# A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

Source: https://onco.cc/trials/nct06879717/  
OnCo record `nct06879717` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Dostarlimab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by iOnctura, active and no longer recruiting.

## Summary

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients is a phase 1/2 interventional study registered as NCT06879717 by iOnctura, with 45 participants planned, started 2025-04-22 and due to reach its primary completion in 2027-01. Interventions recorded: roginolisib, Dostarlimab, Docetaxel. Conditions listed: Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06879717
- Phase: 1/2
- Setting: A Phase I/IIa Study of Roginolisib in Combination With Dostarlimab With or Without Docetaxel in Patients With Advanced Non-squamous NSCLC Who Have Progressed on Standard of Care Immune Checkpoint Therapy and Platinum Doublet Chemotherapy or Standard Immunotherapy Without Chemotherapy (PULMO-1)
- Sponsor: iOnctura
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT06879717: https://clinicaltrials.gov/study/NCT06879717

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Dostarlimab](https://onco.cc/drugs/dostarlimab/), [Roginolisib](https://onco.cc/drugs/roginolisib/)
- companies: [iOnctura](https://onco.cc/companies/ionctura/)

---
JSON: https://onco.cc/api/v1/entities/nct06879717.json